Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, single-dose, double-blind, crossover study to evaluate the pharmacokinetics, safety and abuse potential of IMB-115 in healthy, non-dependent, recreational sedative users

Next Previous
Trial Profile

A randomized, single-dose, double-blind, crossover study to evaluate the pharmacokinetics, safety and abuse potential of IMB-115 in healthy, non-dependent, recreational sedative users

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunobinop (Primary) ; Triazolam
  • Indications Insomnia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Imbrium Therapeutics

Most Recent Events

  • 01 Jul 2019 New trial record
  • 25 Jun 2019 Results published in the Media Release
  • 25 Jun 2019 This trial was conducted in accordance with the U.S. Food and Drug Administration's (FDA) industry guidance on the Assessment of Abuse Potential of Drugs, as reported in an Imbrium Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top